---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029656"
form_type: "8-K"
ticker: null
cik: "0001832415"
company_name: "Better Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:22:53.146733+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Better Therapeutics receives Nasdaq delisting notice for bid price and market value deficiencies

## Summary
- Bid price below $1.00 for 30 consecutive business days; must regain compliance by Dec 13, 2023.
- Market value of listed securities below $35M for 30 consecutive business days; same compliance deadline.
- Company may qualify for a second 180-day period if not compliant by Dec 13, 2023.
- Failure to regain compliance could result in delisting; company plans to monitor and consider options.

## SEC filing metadata
- accession: 0000950170-23-029656
- form_type: 8-K
- cik: 0001832415
- company_name: Better Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832415/000095017023029656/0000950170-23-029656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832415/000095017023029656/bttx-20230616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029656
- JSON: https://secwatch.observer/filing/0000950170-23-029656.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029656.txt

## Key facts
- Listing & Compliance Notices
  Better Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: June 16, 2023, Better Therapeutics, Inc. (the “Company”) received deficiency letters from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement and the market value of listed securities requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum bid price of at least $1 per share (the “Minimum Bid Price Requirement”). Nasdaq Listing Rule 5550(b)(2) requires co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832415/000095017023029656/0000950170-23-029656-index.htm
- Listing & Compliance Notices
  Better Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: June 16, 2023, Better Therapeutics, Inc. (the “Company”) received deficiency letters from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement and the market value of listed securities requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum bid price of at least $1 per share (the “Minimum Bid Price Requirement”). Nasdaq Listing Rule 5550(b)(2) requires co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832415/000095017023029656/0000950170-23-029656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.